Plain-English translation of NCT07001280 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study of garadacimab, a new medication designed to help people with hereditary angioedema (HAE), a rare genetic condition that causes unpredictable swelling episodes. Researchers will follow about 200 patients over four years to see how well this medication prevents or reduces these attacks, how safe it is, and whether it improves daily life—using information from medical records, a symptom diary app, and routine clinic visits.
While earlier clinical trials showed promise for this medication, this study tracks how it actually performs in everyday medical practice for real patients, which can be different from controlled research settings. The goal is to understand whether the medication truly reduces the number and severity of swelling attacks and improves quality of life over time.
You likely qualify if…
You likely don't qualify if…
You will take garadacimab as prescribed by your regular doctor and track your symptoms using an electronic diary on your phone or computer. You'll have routine clinic visits over 48 months (four years), during which your doctor will collect information about your swelling attacks, how you're doing, and any side effects. Researchers will also review your medical records and ask about your healthcare visits and treatment history before you joined the study.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States